Tevogen Bio Holdings Inc. has announced plans to relocate employees from its Philadelphia research and development center to its expanded principal executive offices in Warren, New Jersey. This move follows the expiration of the current lease in Philadelphia in June 2025. The relocation comes after Tevogen Bio Inc., a subsidiary of Tevogen Bio Holdings, amended its lease to double the office space at the New Jersey location and extend the lease term until February 2033.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-013396), on June 03, 2025, and is solely responsible for the information contained therein.